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Abstract
Introduction: The c-Jun coactivator, Jun activation-domain binding protein 1 (Jab1) also known as the fifth
component of the COP9 signalosome complex (CSN5), is a novel candidate oncogene whose aberrant expression
contributes to the progression of breast carcinoma and other human cancers. The mechanism of Jab1 gene
expression and its deregulation in cancer cells remains to be identified. We therefore investigated the
transcriptional regulatory mechanisms of Jab1 expression in human breast carcinoma cells.
Methods: To identify potential regulators of Jab1 transcription, we cloned the 5’ upstream region of the human
Jab1 gene and mapped its transcriptional start site. We identified binding sequences for the CCAAT/enhancer
binding protein (C/EBP) and GATA, as well as a signal transducer and activator of transcription-3 (Stat3) consensus
sequence overlapping the C/EBP site, using 5’- deletion analysis and a gene reporter assay. Mutational analysis of
these binding sites was performed to confirm their roles in promoting Jab1 transcription in breast cancer cells. We
further confirmed these binding sites using electrophoretic mobility shift assays (EMSAs) and chromatin
immunoprecipitation (ChIP) assays. We also analyzed whether the siRNA-mediated inactivation of Stat3 and Src
could reduce Jab1-promoter activity and whether interleukine-6 (IL-6) could mediate increased Jab1 expression
through Stat3 signaling.
Results: We identified binding sequences for C/EBP, GATA, as well as a Stat3 consensus sequence overlapping the
C/EBP site in the promoter region of Jab1. C/EBP-beta2 is a potential transcriptional activator of Jab1 and mutation
of the C/EBP/Stat3 binding site significantly reduced Jab1-promoter activity. In addition, inhibiting Stat3 significantly
reduced Jab1-promoter activation. EMSA and ChIP assays confirmed that C/EBP, GATA1 and Stat3 bind to Jab1
promoter in breast carcinoma cells. We also found that Src, an activator of Stat3, is involved in Jab1-promoter
activation. siRNA knockdown of Src reduced the Jab1-promoter activity, similar to the results seen when Stat3 was
inhibited in breast carcinoma cells. Interestingly, reactivation of Stat3 in normal mammary epithelial cells (MCF-10A,
MCF-10F) is sufficient to reactivate Jab1 expression. Treatment with the cytokine IL-6 resulted in increased Jab1
expression that was blocked by inhibition of Stat3.
Conclusions: These findings reveal a novel mechanism of Jab1 gene regulation and provide functional and
mechanistic links between the Src/Stat3 and IL-6/Stat3 signaling axes that are involved in the activation of Jab1
transcription and regulation of this novel oncogenic protein.
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c-Jun activation domain-binding protein-1 (Jab1) is a
multifunctional protein that regulates cell proliferation
and oncogenesis. Since its identification as a c-Jun coac-
tivator [1], Jab1 has been found to be an integral com-
ponent of the COP9 signalosome (CSN) complex, a
multifunctional protein complex involved in modulating
signal transduction, gene transcription, and protein sta-
bility [2-4]. Jab1 is the fifth subunit of the CSN and is
also referred to as CSN5. One of the most recognized
functions of the CSN is the deneddylation of the cullin-
RING-ubiquitin ligase (CRL) and this function is reliant
on the Jab1 MPN domain metalloenzyme (JAMM) motif
that serves as the catalytic center [5,6]. Jab1 exists not
only as a member of the CSN holocomplex and smaller
CSN complexes, but also as a monomer with a number
of different unique protein interactions and functions
outside of the CSN.
Jab1 functionally inactivates several key negative regu-
latory proteins by affecting their subcellular localization,
degradation, phosphorylation, and deneddylation,
thereby acting as a positive regulator of cellular prolif-
eration. Through these interactions, Jab1 plays a crucial
role in the inactivation of several key tumor suppressors,
including cyclin-dependent kinase inhibitor p27
Kip1, p53,
and Smad4/7 [7-10]. It can also interact with several
important intracellular signaling molecules including
hypoxia inducible factor-1 alpha (HIF-1a), macrophage
migration inhibitory factor (MIF), E2F1, and cullin 1
(CUL-1) [11,12].
Abnormal overexpression of Jab1 has been detected in
several types of cancer in humans and in some cases
correlates with poor prognosis and low-level expression
of p27 [13-18]. However, the molecular mechanism for
up-regulation of Jab1 in cancer cells is still unclear. Our
studies have shown that Jab1 and p27 protein levels are
inversely correlated in invasive breast carcinoma speci-
mens and that Jab1 is highly expressed in breast tumor
samples relative to paired normal-tissue samples [14].
Jab1, along with the oncogene Myc, reside on the fre-
quently amplified region on chromosome 8 and were
identified to induce a wound signature in human breast
cancer cells [19]. Further investigations identified the
isopeptidase activity of Jab1 to be critical for its ability
to promote transformation and progression in breast
epithelial cells and inhibition of this activity is sufficient
to block breast cancer progression driven by MYC and
RAS [20]. These findings suggest that Jab1 is an impor-
tant regulator in cancer development and preclinical
studies suggest that inhibition of Jab1 delays tumor
growth [14].
Given the frequency of Jab1 overexpression in human
cancers and its potential role in the development of can-
cer, identifying the mechanism by which Jab1
overexpression occurs would be of great interest. The
extent to which Jab1 amplification on chromosome 8q is
responsible for its frequent overexpression in cancer has
not yet been investigated. However, additional mechan-
isms of regulation through transcriptional control are
likely to also be of importance and may link its regulation
to upstream signaling pathways. We hypothesize that
overexpression of Jab1 in breast cancer can be attributed
to an increase in transcriptional activity over that seen in
normal tissue. We therefore studied the transcriptional
regulation of Jab1 in breast cancer cells. In this present
study, we describe the cloning and characterization of the
human Jab1 promoter. We also identify a region whereby
CCAAT/enhancer binding protein-beta (C/EBP-b), signal
transducer and activator of transcription-3 (Stat3), and
GATA1 induce Jab1 transcription and identify a potential
upstream oncogenic signaling molecule that may be key
to the regulation of Jab1 expression in cancer. The region
we describe here has also recently been identified by
another group to contain a T-cell transcription factor
(TCF)-4 and Sp1 binding site that was found to be
important for transcription and activated by human epi-
dermal growth factor receptor (HER)-2 activation of the
AKT/b-catenin pathway [21], which points to the impor-
tance of this region in driving the transcription of Jab1
and possibly linking its expression to potent oncogenic
signaling pathways.
Materials and methods
Cell lines, reagents and antibodies
The human breast cancer cell lines, MCF7, MDA-MB-
468, MDA-MB-231, BT-474, ZR-75-1, BT-549, MDA-
MB-453, T47D and non-tumorigenic human breast
epithelial MCF-10A, MCF-10F, HMEC, and 184A, were
purchased from the American Type Culture Collection
(Manassas, VA, USA). None were derived directly from
tumor tissue for the purposes of this study. MCF7 cells
were grown in DMEM. Breast cancer cells were grown
in RPMI medium supplemented with 10% FBS. MCF-
10A and MCF-10F cells were grown in 50% DMEM,
50% F-12 medium supplemented with 5% horse serum,
100 units/ml penicillin, 100 μg/ml streptomycin, 10 μg/
ml insulin, 100 ng/ml cholera toxin, 0.5 μg/ml hydrocor-
tisone, 20 ng/ml recombinant human epidermal growth
factor, and 1 mM CaCl2. The following antibodies were
used in the study: C/EBP-a (N-19), C/EBP-b (C-19),
GATA-1 (H-200), and Stat3 (C-20) (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). The following antibodies
were obtained from Cell Signaling (Danvers, MA, USA):
Src, Phospho-Stat3(Y705), b-Tubulin, and b-actin. Anti-
Flag was obtained from Sigma-Aldrich (St. Louis, MO,
USA). IL-6 was obtained from Invitrogen (Carlsbad, CA,
U S A )a n du s e da t4 0n g / m L .T h eS t a t t i ci n h i b i t o r
(Sigma, St. Louis, MO, USA) was used at 20 nM.
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An antisense primer, P1 was designed 5’ of the ATG
translation site of the Jab1 gene and end-labeled with T4
polynucleotide kinase and
32P-g-ATP, followed by purifi-
cation using Nu-Clean D25 columns (Shelton Scientific-
IBI, Peosta, IA, USA). Total RNA was isolated from
MDA-MD-231 cells using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA), and 20 μgo fR N Aw a sh y b r i d i z e d
with 1 × 10
6 c.p.m. of
32P-labeled P1 oligonucleotide.
The protocol for the Primer Extension System-AMV
Reverse Transcriptase (Promega, Madison, WI, USA) was
followed. The size of the extended product was deter-
mined by electrophoresis on a 6% polyacrylamide gel
containing 6 M urea. To determine the size of the primer
extended fragment, the labeled Promega marker and a
sequencing reaction with Jab1 cDNA as template and
primer P1 using the SequiTherm Excel II DNA Sequen-
cing Kit (Epicentre, Madison, WI, USA) were run simul-
taneously on the gel.
Computer analysis
Transcription factor binding sites were predicted using
Genomatix software (Munich, Germany); the MatIn-
spector program, which uses TRANSFAC matrices; and
the WebGene HCtata program’s Hamming clustering
method for TATA signal prediction in eukaryotic genes.
Cloning and analysis of the human Jab1 promoter
To clone the 5’-flanking region of the human Jab1 gene,
a bacterial artificial chromosome clone containing the
region corresponding to Jab1 was used as a template for
PCR. The amplified DNA fragments were subcloned
into the luciferase reporter vector pGL3 (Promega,
Madison, W, USA). Progressive deletion mutants of the
pGL3-Jab1 promoter were created by PCR. The integrity
of constructs was confirmed by DNA sequencing. The
following primers were used: +83R, -2006F, -2958F,
-946F, -658F, -472F, -344F, -127F, and -59F (Table 1).
PCR and RT-PCR
The PCR reaction contained 100 ng of DNA template,
1.5 mM MgCl2, 0.2 mM dNTP (Roche Applied Science,
Indianapolis, IN, USA), 1 uM of primers, and Taq High
Fidelity DNA polymerase (Invitrogen, Carlsbad, CA,
USA).
The reverse transcriptase (RT) assay was performed
from 2 μg of total RNA using Superscript II RT (Invitro-
gen, Carlsbad, CA, USA) according to the manufac-
turer’s procedure. A reaction without RT was performed
in parallel to ensure the absence of genomic DNA con-
tamination. PCR amplification was carried out as
described previously [22]. Conditions for the PCR reac-
tion consisted of an initial denaturation step at 94°C for
5 minutes, followed by 30 cycles of 30 seconds at 94°C,
30 seconds at 60°C, and 30 seconds at 68°C. After a
final extension at 72°C for 10 minutes, PCR products
were resolved on 1.2% agarose gels and visualized by
ethidium bromide transillumination under UV light. Pri-
mers used were: Jab1 F296-314, Jab1 R1094-1076, Jab1
R883-864, GAPDH F, and GAPDH R. For these and all
following primer sequences please refer to Table 1.
Transient transfection with reporter constructs and
luciferase assay
MCF7, MDA-MB-231, and MDA-MB-468 cells were
plated into 24-well tissue culture dishes at 4 × 10
4 cells/
well 24 hours before transfection. Transfections were
performed in triplicate according to the manufacturer’s
protocol using Lipofectamine PLUS reagent (Invitrogen,
C a r l s b a d ,C A ,U S A ) .B r i e f l y ,0 . 4μg reporter plasmid
Jab1-Luc (Firefly luciferase) together with 10 ng of pRL
(Renilla luciferase) were cotransfected. Luciferase assays
were performed 36 hours after transfection using a
Dual-Luciferase Reporter Assay System (Promega, Madi-
son, W, USA). Firefly and Renilla luciferase activities
were read on a Monolight 3010 luminometer (BD
Bioscience, Rockville, MD, USA). Firefly luciferase activ-
ity was normalized to Renilla luciferase readings in each
well. Each experiment was conducted at least twice in
triplicate.
Mutagenesis of the Jab1 promoter
Site-directed mutagenesis of CEBP and GATA1 was per-
formed according to the QuickChange II method (Stra-
tagene, La Jolla, CA, USA). The following mutagenic
primers were used: CEBP-Mut, GATA1-Mut, and
GATA1-Del (see Table 1 for sequences). All mutants
were verified by sequencing.
Nuclear extract preparation and electrophoretic mobility
shift assay
Nuclear extracts were prepared as previously described
[1]. Briefly, MCF7 and MDA-MB-468 cells were lysed in
10 mM HEPES-KOH (pH 7.9), 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA, 1 mM DTT, and protease inhi-
bitor cocktail (Roche Applied Science, Indianapolis, IN,
USA). After incubation for 10 minute on ice, nuclei
were recovered by centrifugation at 3,000 × g at 4°C for
one minute and resuspended in 20 mM HEPES-KOH
(pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1
mM DTT, and protease inhibitor cocktail. Protein con-
centrations were determined using the DC Protein
Assay (Bio-Rad Laboratories, Hercules, CA, USA). The
following double-stranded DNA oligonucleotides were
used in the electrophoretic mobility shift assays
(EMSAs): -462/-436 CEBP-WT, -462/-436 CEBP-M1,
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Table 1 for sequences).
Oligonucleotides were end-labeled with [g-
32P] ATP
(MP Biomedicals, Solon, OH, USA) by T4 polynucleo-
tide kinase (New England Biolabs, Ipswich, MA, USA)
and purified with Quick Spin G-50 Columns (Roche
Applied Science, Indianapolis, IN, USA). Pre-binding of
5 μg of nuclear extract to 0.05 mg/mL poly(dI:dC)
(Roche, Applied Science, Indianapolis, IN, USA) was
performed in a buffer containing 20 mM HEPES (pH
7.4), 0.1 mM EDTA (pH 8.0), 75 mM KCl, 2.5 mM
MgCl2, 1 mM DTT, and 5% glycerol for 20 minutes at
room temperature (22 to 24°C) before addition of
60,000 c.p.m. of labeled probe. For competition assays,
25- and 100-fold excess cold competitor oligonucleotide
duplex was added to the reaction buffer 10 minutes
before addition of the labeled probes. For supershift
assays, antibodies were added for 20 minutes at 4°C
prior to addition of the labeled probe. Reactions were
resolved by electrophoresis on a 4.5% nondenaturing
polyacrylamide gel run in 0.5 × TBE, vacuum-dried with
heat, and exposed to film at -80°C.
Chromatin immunoprecipitation (ChIP) assay
The manufacturer’s protocol for the chromatin immu-
noprecipitation (ChIP) Assay Kit (Upstate Biotechnol-
ogy, Temecula, CA, USA) was followed. Briefly, MCF7
cells or MDA-MB-231 cells transfected with control
pcDNA vector or C/EBP-b2 and were incubated with
1% formaldehyde for 20 minutes at 37°C. Cells were col-
lected, lysed, sonicated, and incubated with 4 μg of anti-
bodies to C/EBP-a, C/EBP-b, GATA-1, Stat3, or b-actin
overnight. PCR was used to amplify DNA bound to the
immunoprecipitated histones after reversing the histone-
DNA cross-links. The following primers were used for
PCR: -472F and -344R (see Table 1 for sequences).
Transfection of small interfering RNA oligonucleotides
Small interfering RNA (siRNA) for Stat3, Src,a n dC o n -
trol (LUC) were obtained from Dharmacon (Lafayette,
CO, USA). Oligonucleotides were transfected using Oli-
gofectamine (Invitrogen, Carlsbad, CA, USA) following
the manufacturer’s protocol. For luciferase assay experi-
ments, MDA-MB-468 cells were plated at 4 × 10
4 cells
per well in a 24-well tissue culture dish. siRNA (20
Table 1 Sequences of oligonucleotides used in RT-PCR, primer extension, cloning site- directed mutagenesis, EMSA
and ChIP
Oligonucleotide Sequence (5’ à3 ’) Purpose
Jab1 F296-314 ATCTCAGCATTGGCTCTGC RT-PCR
Jab1 R1094-1076 TAACCTGAGACATCAATC RT-PCR
Jab1 R883-864 AGAACTCAACGTATTCACCC RT-PCR
GAPDH F CCACCCATGGCAAATTCCATGGCA RT-PCR
GAPDH R TCTAGACGGCAGGTCAGGTCCACC RT-PCR
P1 CGCTCCCGGACGCCGCC Primer extension
+83R CTGAAAGCTTCGCTCCCGGACGCCGCC Cloning
-2006F CTGACTCGAGGTGGTAGTGAGAGG Cloning
-2958F CTGACTCGAGCGCATGGGAACCAA Cloning
-946F TGAACTCGAGCCTGCTCCCTGTGTC Cloning
-658F CTGACTCGAGCCCACTGCCTCCTCG Cloning
-472F CTGAGCTAGCCAACAGACAGCCTT Cloning
-344F CTGACTCGAGGAGGCCGAGCCTGC Cloning
-127F TGAGCTAGCGTCCCGGAAAGGTCCCC Cloning
-59F TGACTCGAGCTGCCCCAAGAGTC Cloning
-31F CTGAGCTAGCGTTCCCGTGGTGCGG Cloning
CEBP-Mut GCCTTACCTTTTAGTCTTTCctgAAACTTATCTC Site-directed mutagenesis
GATA1-Mut CAACAAACTTgagTCATTTAAGGTACCTATACCC Site-directed mutagenesis
GATA1-Del GTCTTTCAACAAACTT....CATTTAAGGTACC Site-directed mutagenesis
-462/-445 CEBP WT CCTTACCTTTTAGTCTTTCAACAAACT EMSA
-462/-445 CEBP Mut CCTTACCTTTTAGTCTTTCctgcAAACT EMSA
-444/-417 GATA1 WT AATCATTTATCTCATTTAAGGTACC EMSA
-444/-417 GATA1 M1 GGAGTCATTTAAGGTACCTATACCC EMSA
-472F CTGACTCGAGCAACAGACAGC ChIP
-343R CTGAAAGCTTCGCAGGCT ChIP
Lower-case letters represent mutated oligonucleotides.
ChIP, chromatin immunoprecipitation; Del, deletion; EMSA, electrophoretic mobility shift assay; F, forward; Mut, mutant; M1, mutant-1; P, primer; R, reverse; RT-
PCR, reverse-transcription polymerase chain reaction; WT, wild-type.
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ium without antibiotics. The -472 Jab1-Luc construct
and pRL were cotransfected 24 hours later using the
manufacturer’s protocol for Lipofectamine PLUS trans-
fection reagent. Luciferase assays were performed after
48 hours.
Results
Mapping the transcription initiation start site of the
human Jab1 gene
To determine the transcription start site of the Jab1
gene, primer extension analysis was performed. An anti-
sense oligonucleotide (P1 primer) was synthesized corre-
sponding to the sequence located at the ATG
translational start site according to the published
sequence [GenBank accession no. NT008183]. The P1
primer was radio-labeled and extended using avian mye-
loblastosis virus reverse transcriptase and analyzed on a
polyacrylamide-urea gel along with a DNA cycle sequen-
cing reaction using the same primer. The primer exten-
sion experiment revealed an extension product of 71
nucleotides using the P1 primer (Figure 1a). The nucleo-
tide 71 bp upstream of the ATG translation start site
was designated the +1 transcription initiation site in the
numbering of the nucleotide sequence throughout this
study.
Identification of the transcription elements located in the
Jab1 promoter
Based on the determined location of the transcription
start site, we analyzed the Jab1 5’ flanking region for a
functional promoter. Using the MatInspector program,
which uses TRANSFAC transcription factor binding site
matrices, we identified a number of putative transcrip-
tion factor binding sites upstream of the Jab1 transcrip-
tion start site (Figure 1b). A typical TATA box [23] was
found 40 bp upstream of the transcription start site,
along with a CAAT box at -99 bp. A number of putative
transcription factor-binding elements were present in
the promoter sequence, including STAT, ELK, p53, E2F,
C/EBP, GATA, c-Myb, and AP-1.
Identification of Cis-Acting elements within the Jab1 gene
promoter
To analyze the mechanisms responsible for transcrip-
tional regulation of Jab1, luciferase constructs were gen-
erated to evaluate Jab1 promoter activity. A fragment of
the human Jab1 promoter region from -2958 to +68
was amplified, sequenced, and subcloned into the luci-
ferase reporter vector pGL3. To identify regulatory
sequences that are important for transcriptional control
of the Jab1 gene, we created a series of 5’-deletion con-
structs of the full length Jab1 promoter and analyzed for
their ability to drive the expression of luciferase in
MCF7 breast cancer cells (Figure 2a). Serial 5’-deletion
mutations of the full-length promoter revealed a pattern
of functional activity in transfected cells. The results
suggest that the core promoter elements that drive max-
imal promoter activity are within the sequence spanning
-472 and -345 upstream of the transcription initiation
site, as the -344 Jab1-Luc construct displayed a marked
loss of promoter activity (Figure 2a). Similar patterns of
activity were seen in other breast cancer cell lines
including BT-549, MDA-MB-231, SKBR3, and BT-474
(data not shown). Additionally, we evaluated the promo-
ter strength in mammary tumor cells versus non-tumor
Figure 1 Identification of the transcriptional start site and
promoter region of the human Jab1 gene.( a) Primer extension
(PE) analysis was performed using an oligonucleotide corresponding
to the antisense sequence at the translational start site (+1). A
sequencing reaction using the same primer labeled with [g -
32P]
ATP was included as a size marker and is shown on the left. An
extension product of 71 bp was observed. (b) Sequence of the
promoter region of Jab1, with potential regulatory elements
(underlined) identified according to the TRANSFAC databases. bp,
base pairs; Jab1, c-Jun activation domain-binding protein-1.
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Page 5 of 16Figure 2 5’ deletion of the Jab1 promoter analysis reveals increased activity in breast cancer cells compared with normal cells.( a)
Identification of the minimal promoter region of Jab1 using progressive deletion of the 5’ region in luciferase reporter constructs. The plasmids
were cotransfected with Renilla luciferase plasmid pRL-null (transfection control) into MCF7 cells, and luciferase activity was assayed. Values
represent mean ± standard error of triplicate experiments. Luciferase assays shown in subsequent figures were performed similarly. (b) Jab1
promoter 5’ deletion constructs were transfected into MCF7 and MCF-10A cells and subjected to luciferase reporter assays. Promoter activity was
higher in MCF7 epithelial breast cancer cells than in non-tumorigenic epithelial MCF-10A cells. Deletion of the region -472 to -344 resulted in a
loss of promoter activity in both cell lines. (c) A panel of breast cancer cells and normal mammary cells were transfected with the -472 Jab1-Luc
construct. Significance is noted as * P < 0.05 and ** P < 0.01 and was determined by t-test. (d) Jab1 protein levels for the cell lines in (c) were
detected by western blotting, b-actin is shown as a control. Jab1, c-Jun activation domain-binding protein-1.
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MCF7 breast cancer cells when observing the -472 con-
struct than in MCF-10A normal mammary epithelial
cells (Figure 2b). Further analysis of a panel of breast
cancer cell lines including BT-474, ZR-75-1, MCF7, BT-
549, and MDA-MB-453 revealed higher Jab1 promoter
activity compared to normal mammary epithelial cells
MCF-10A, HMEC and 184A (Figure 2c). Jab1 protein
levels were also found to be higher in the panel of
breast cancer cells compared with the normal mammary
epithelial cells HMEC and MCF-10A (Figure 2d). There-
fore, the transcription factors responsible for promoting
Jab1 transcription are either not present in normal cells
or not as active as in tumor cells. Another possibility is
that normal cells may express transcription suppressors
acting on this region. In Figure 2b, the activity of the
deletion constructs demonstrated differing ratios of luci-
ferase activity between MCF7 and MCF-10A suggesting
that different dominant regulatory factors may exist in
each of these cell lines. However, interestingly, the same
differential in promoter activity was seen between the
-472 and -344 constructs in both cell lines.
Identification of C/EBP and GATA transcription elements
located in the -472/-345 region of the Jab1 promoter
Our data suggest that the -472 to -345 (-472/-345)
region is key to driving the transcription of Jab1.W e
therefore sought to identify the transcription factors that
regulated Jab1 through this region. Using the TRANS-
FAC database, we identified a number of putative tran-
scription factor binding sites in the -472/-345 region,
including sites for C/EBP (-444/CAAC/-441) and
GATA-1 (-435/TATCT/-431) (Figure 1b). Because these
transcription factors are activated in some cases of
tumorigenesis [24,25], we speculated that they contribu-
ted to the increased transcription of Jab1.
C/EBPs are a family of basic leucine-zipper transcrip-
tion factors, including C/EBP-a, C/EBP-b,- ∂,- ε,- g, and
-ζ [26]. Of these, C/EBP-a,- b,a n d- ∂ are expressed in
the mammary gland, with C/EBP-b proposed to play a
role in breast cancer [27,28]. The GATA family of tran-
scription factors is required for erythroid and megakar-
yocytic differentiation [29]. Unlike other GATA
members, GATA-1 has not been associated with any
solid tumors, but mutations in GATA-1 are associated
with essentially all cases of acute megakaryoblastic leu-
kemia in children with Down syndrome [30].
To pinpoint the functional significance of the C/EBP
and GATA-1 binding sites detailed within the Jab1 pro-
moter we performed promoter and EMSA analysis of
these regions. Cloning of this region in front of the
-105/+83 sequence containing the TATA and CAAT
boxes was sufficient to drive Jab1 promoter activity (Fig-
ure 3a). To determine whether these putative elements
are capable of binding transcription factors, we per-
formed a series of EMSA experiments with nuclear
extracts from MCF7 breast cancer cells. The oligonu-
cleotides and mutants for the C/EBP and GATA-1 bind-
ing sites are shown in Figure 3b. The -462/436 and
-435/-417 probes showed transcription factor binding
activity to the DNA containing the C/EBP and GATA-1
binding sites, respectively (Figure 3c). The cold specific
oligonucleotides competed efficiently for binding,
whereas a cold mutant competitor containing a muta-
tion in the C/EBP or GATA-1 binding site did not.
Further, a supershift was observed when the oligonu-
cleotides were incubated with antibodies to C/EBP-b
and GATA-1 (Figure 3c).
To assess whether any of these sites is important for
expression of Jab1, each was mutated individually in
luciferase reporter plasmids. We introduced mutations
in the -472/-345 region of the Jab1 promoter to disrupt
C/EBP and GATA-1 binding and compared their activ-
ity with the -472 Jab1-Luc promoter construct in transi-
ent transfection assays. Mutation of either C/EBP or
GATA-1 binding sequence reduced Jab1 promoter
activity by approximately 40% and 20%, respectively, and
mutation of both sites resulted in a reduction of
approximately 75% (Figure 3d). Interestingly, C/EBP and
GATA binding sites homology from the human and
mice promoter regions were found very well conserved
[see Figure S1 in Additional file 1].
C/EBP-a, C/EBP-b, and GATA-1 transactivate the Jab1
promoter
Next, we examined which of the C/EBP and GATA
family members are important for Jab1 promoter activ-
ity. We cotransfected different members of the C/EBP
and GATA family, C/EBP-a,C / E B P - b,o rC / E B P - δ,o r
GATA1-6, into MCF7 cells, along with the -472 Jab1-
Luc plasmid (Figure 4a). Compared with control cells
transfected with vector alone, cells transfected with C/
EBP-a,C / E B P - b, or GATA-1 showed the greatest
increase in -472 Jab1-Luc reporter activity (2.2-, 3.0-,
and 2.6-fold, respectively). GATA-2 and GATA-3 also
showed a significant increase in activity but for the pur-
pose of this study were not studied in detail.
Interestingly, the transcription factor C/EBP-b has
been associated with breast cancer [27,31]. It is trans-
lated into three different isoforms: C/EBP-b1, a 55-kDa
liver-enriched activating protein (LAP1); C/EBP-b2, a
42- to 46-kDa protein also called LAP2 and; C/EBP-b3
a 20-kDa liver-enriched inhibitory protein (LIP) [25,32].
Of the three C/EBP-b isoforms, LAP2 has been specifi-
cally observed in breast cancer, and overexpression of
this isoform can induce epithelial-mesenchymal transi-
tion [28]. LIP, however, is unable to activate gene tran-
scription, but is still able to bind to DNA and dimerize,
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Page 7 of 16Figure 3 Functional analysis of the Jab1 promoter.( a) The -472/-312 region contains a regulatory sequence that is sufficient to activate
transcription of the Jab1 promoter when cloned in front of the TATA and CAAT boxes. MCF7 cells were transfected with either the -105/+83-
Luc or -472/-312, and -105/+83 Jab1-Luc constructs and subjected to luciferase reporter assays. Values were compared with the -105 Jab1-Luc
reporter by Student’s t test, * P < 0.01. (b) Sequence of the probes used in EMSA assays. The probes span the sequence from -440 to -414 or
from -412 to -389 of the Jab1 promoter and encompass the C/EBP or GATA sites. (c) Binding of C/EBP and GATA-1 to the Jab1 promoter. EMSAs
showing binding of nuclear proteins C/EBP and GATA-1 to the C/EBP and GATA-1 binding sites of the Jab1 promoter. End-labeled
oligonucleotide probes corresponding to the -440/-414 (C/EBP) or -413/-389 (GATA-1) regions of the WT Jab1 promoter sequence were
incubated with nuclear extract proteins from MCF7 cells and separated on a 4.5% polyacrylamide gel. Lane 1 shows binding between probe and
nuclear extract. Specificity was determined by addition of 50 and 100 molar excess of unlabeled specific cold probe, and mutant probe as
specific and nonspecific (NS) competitors as indicated. Lane 4 shows complexes observed in the presence of probes containing mutations in C/
EBP or GATA-1. Supershift of the complex was observed following incubation with C/EBPb or GATA-1 antibodies as shown in the right panels.
(d) MCF7 cells were transfected with the -472 Jab1-Luc, -472 C/EBP mutant (Mut1
C/EBP), -472 GATA-1 mutant (Mut 2
GATA1), Mut1+2, or -344
Jab1-Luc plasmids. Mutation of the C/EBP(Mut1
C/EBP) and GATA-1 (Mut2
GATA1) binding sites reduced Jab1 promoter activity by about 60% and
20%, respectively, and by 75% when mutated together. The firefly luciferase activity of each sample was normalized to that of Renilla luciferase
(pRL). Data present the mean ± standard deviation of three independent experiments. All values were compared with the -472 Jab1-Luc reporter
by Student’s t test. C/EBP, CCAAT/enhancing binding protein; EMSA, electrophoretic mobility shift assay; Jab1, c-Jun activation domain-binding
protein-1; NS, nonspecific binding; SS, supershift.
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Page 8 of 16Figure 4 C/EBP-a,C / E B P - b and GATA-1 transactivate the Jab1 promoter.( a) -472/+83 Jab1-Luc reporter plasmid was cotransfected with
expression plasmids for C/EBP-a, C/EBP-b, C/EBP-δ, and GATA-1-6. The results are presented as fold activation compared with cells transfected
with pcDNA3.1 vector control. All values were compared with the vector control by Student’s t test. (b) Left, LAP1 (C/EBP-b1), LAP2 (C/EBP-b2),
or LIP (C/EBP-b3) plasmids, along with the -474 Jab1-Luc promoter construct, were cotransfected with the Renilla luciferase plasmid pRL-null
(transfection control) into MCF7 cells, and luciferase activity was assayed. Right, western blot analyses to demonstrate the protein expression of
LAP1, LAP2 and LIP. (c) Endogenous expression of the C/EBPb isoforms (LAP1, LAP2, and LIP) and GATA-1 were detected at higher levels in
breast cancer cell lines compared with normal mammary epithelial cells by western blot analysis. (d) Identification of proteins in complexes by
ChIP assays. Antibodies to b-actin, C/EBP-a, C/EBP-b, or GATA-1 were used to immunoprecipitate protein/DNA complexes from the sonicated
lysates of MCF7 cells. After reversing the cross-linking, DNA was precipitated and PCR was performed using primers to amplify the -472/-344
promoter DNA. As a negative control, primers for the upstream promoter region -642/-475 were used. Bottom panel represents quantification of
the data with ImageJ software. C/EBP, CCAAT/enhancing binding protein; ChIP, chromatin immunoprecipitation; Jab1, c-Jun activation domain-
binding protein-1; LAP, liver-enriched activating protein; LIP, liver-enriched inhibitory protein; PCR, polymerase chain reaction; pRL, Renilla
luciferase reporter vector; RT-PCR, reverse transcription polymerase chain reaction.
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Page 9 of 16and therefore acts as a dominant negative [27]. It has
been suggested that the LAP/LIP ratio may be an
important indicator of C/EBP-b transcription [25]. We
found that LAP2 activates the Jab1 promoter (over two-
fold), whereas LAP1 had little effect and LIP decreased
activity by about 16% (Figure 4b). Further, analysis of
the C/EBPb isoforms in breast cancer cells compared
with normal, revealed higher levels of the LAP-1 and -2
isoforms in MCF7, MDA-MB-468 and MDA-MB-231
breast cancer cells compared with normal mammary
epithelial cells HMEC and MCF-10A (Figure 4c). Inter-
estingly, the LIP expression was also expressed at higher
levels in the breast cancer cells compared with normal
(Figure 4c). This in line with the increased endogenous
Jab1 expression detected in these breast cancer cells
compared with the normal mammary epithelial cells as
shown in Figure 2d. We also detected higher GATA-1
expression in the breast cancer cells compared with nor-
mal mammary epithelial cells and taken together could
be a driving force in leading Jab1 expression in breast
cancer.
C/EBP-a, C/EBP-b, and GATA-1 bind to the Jab1 promoter
To further determine whether C/EBP isoforms and
GATA-1 bind to the Jab1 promoter, we performed
ChIP assays on chromatin obtained from MCF7 cells
(Figure 4d). When chromatin was incubated with b-
actin, no product was observed. When chromatin was
incubated with antibodies to C/EBP-a,C / E B P - b,a n d
GATA-1 and the -472/-344 region was amplified by
PCR, a product was observed. These data suggest that
C/EBP-a, C/EBP-b, and GATA-1 bind specifically to the
-472/-344 region of the Jab1 promoter.
Stat3 enhances the activity of C/EBP-a and C/EBP-b on
the Jab1 promoter
The C/EBP transcription factors form heterodimers with
other C/EBP family members and other transcription
factors. We observed that Jab1-driven luciferase reporter
activity increased upon addition of conditioned medium
to MCF7 cells (data not shown). One of the pathways
activated by conditioned medium is the Stat3 pathway,
which has also been linked with breast tumorigenesis
[33]. Moreover, Stat3 has been shown to interact with
the C/EBP transcription factors and increase their activ-
ity [24]. We therefore investigated whether Stat3 can
transactivate the Jab1 promoter, alone or in combina-
tion with C/EBP-a or C/EBP-b. Stat3 alone increased
Jab1 promoter activity, but Stat3 along with C/EBP-a
and C/EBP-b synergistically increased Jab1 promoter
activity (Figure 5a), suggesting that Stat3 interacts with
C/EBP on the Jab1 promoter. To that end, we observed
a STAT general consensus site (TTN5AA) [34] that
overlaps the C/EBP site within the Jab1 promoter
sequence (-472 to -345) and was not identified by tran-
scription factor database searches (Figure 5b). Stat1,
Stat3, Stat4, and Stat92E all bind to this generalized
consensus site [34,35].
We next performed a ChIP assay to determine
whether Stat3 could bind with C/EBP-b2 co-operatively
to the Jab1 promoter using MDA-MB-231 cells, which
have constitutively activated Stat3. Since C/EBP-b2( o r
LAP2) seems to be a major activator of the Jab1 promo-
ter (Figure 4), we next focused only on C/EBP-b2. Bind-
ing of Stat3 to the Jab1 promoter was increased greater
than seven-fold when C/EBP-b2 was transfected into the
cells (Figure 5c). Taken together, these data suggest that
C/EBP-b2a n dS t a t 3b i n dt ot h eJab1 promoter to
increase Jab1 promoter activities.
We further investigated whether inhibition of Stat3
affects Jab1 promoter activity in MDA-MB-468 cells,
which have constitutively activated Stat3. Expression of
a dominant-negative mutant of Stat3 reduced over 80%
Jab1 promoter activity (Figure 5d). The EEE/VV muta-
tion renders the protein incapable of DNA binding [36].
Expression of exogenous wild type Stat3 increased Jab1
expression, whereas the dominant-negative EEE/VV
mutation reduced Jab1 protein levels (Figure 5e).
Inhibition of Stat3 and Src decrease Jab1 promoter
activity and protein expression
To further demonstrate the regulation of Jab1 by Stat3,
we examined the effect of inhibition of Stat3 and also
its upstream activator Src using siRNA [37,38]. Inhibi-
tion of Stat3 and Src by siRNA resulted in a dramatic
reduction of Jab1 promoter activity (Figure 6a), mRNA
levels (Figures 6b and 6c), and Jab1 protein expression
(Figure 6d). Similar results were obtained with MDA-
MB-231 cells (data not shown). Collectively, these
results demonstrate that the Src/Stat3 signaling pathway
plays an important role in the regulation of Jab1
transcription.
Stat3-induced Jab1 transcriptional activation and protein
expression
To determine the biological significance of Stat3-
mediated Jab1 expression, the role of Stat3 in normal
human breast epithelial cells was investigated. As Jab1
expression in normal mammary epithelial cells is low,
we asked whether overexpression of Stat3 could enhance
Jab1 transcription in these cells. Ectopic expression of
Stat3 in normal mammary epithelial cells (MCF-10A
and MCF-10F) resulted in increased Jab1 mRNA and
protein levels (Figures 7a and 7b). Therefore, the Stat3
transcription factor is in part responsible for promoting
Jab1 transcription in breast cancer cells and is either
not present or not as active in the MCF-10A and MCF-
10F cells.
Shackleford et al. Breast Cancer Research 2011, 13:R65
http://breast-cancer-research.com/content/13/3/R65
Page 10 of 16We further investigated whether an upstream activator
of Stat3, the cytokine IL-6, could be driving increased
Jab1 expression. Treatment with IL-6 for 30 minutes
increased phosphorylation of Stat3 on tyrosine 705 and
resulted in increased Jab1 mRNA (Figure 7c) and pro-
tein levels (Figure 7d) within the short time of 30 min-
utes, 1 hour, and 4 hours that was partially blocked by
the addition of the Stat3 inhibitor Stattic. The same
trends were observed in the breast cancer cell line T47D
and the mammary epithelial cells, MCF-10A. IL-6 also
resulted in increased Jab1 promoter activity in MCF7
and T47D cells [See Figure S2 in Additional file 1].
Taken together, it is evident that both IL-6 and Src
signaling through Stat3 is contributing to Jab1 transcrip-
tion and increased expression in breast cancer. Further,
it is possible that Stat3 and C/EBPb could be binding to
the Jab1 promoter either separately or together to med-
iate increased Jab1 transcriptional activity. A proposed
Figure 5 Stat3 can synergize with C/EBP-a and C/EBP-b to transactivate the Jab1 promoter.( a) The -472/+83 Jab1-Luc reporter plasmid
was cotransfected with expression plasmids for C/EBP-a, or C/EBP-b. Plasmid amounts were normalized by the addition of empty expression
plasmid. Following transfection, MCF7 cells were incubated for another 36 hours. The results are presented as fold activation compared with cells
transfected with pcDNA vector control. (b) A potential STAT-binding element (TTN5AA consensus sequence) overlaps the C/EBP binding site
(CAAC). (c) Binding of Stat3 to the Jab1 promoter is enhanced by the addition of C/EBP. MDA-MB-231 cells were transfected with either control
of C/EBP-b2 and collected for ChIP assays using an antibodies against Stat3 and primers for the -472/-344 region of the Jab1 promoter. Right
panel represents quantification of the band intensities and normalized to the input with ImageJ software. (d) MDA-MB-468 cells were
cotransfected with either pcDNA control, a Flag-tagged Stat3 (Flag-Stat3), or Flag-tagged dominant negative (DN)-Stat3
EEE/VV, along with the -472
Jab1-Luc construct, and subjected to luciferase reporter assays. (e) Overexpression of Flag-tagged Stat3 increased Jab1 protein levels while a
reduction was seen with Flag-DN- Stat3
EEE/VV. C/EBP, CCAAT/enhancing binding protein; ChIP, chromatin immunoprecipitation; Jab1, c-Jun
activation domain-binding protein-1.
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Page 11 of 16model for the activation of Jab1 transcription is shown
in Figure 7e.
Discussion
Jab1 is commonly overexpressed in patients with breast
cancer as well as other tumor types. The mechanism by
which Jab1 is regulated is currently not known and our
data suggest that this may occur at the transcriptional
level. In this study, the Jab1 promoter was analyzed to
identify the molecular basis of Jab1 gene expression and
to give insight into the mechanisms by which Jab1 is
overexpressed in cancer. Jab1 promoter analysis led to
Figure 6 Inhibition of Stat3 and Src by siRNA reduces Jab1 promoter activity in breast carcinoma cells.( a) MDA-MB-468 cells were
cotransfected with siRNA targeting Stat3 (siStat3) or Src (siSrc), along with either the -472 Jab1-Luc construct or -472-Mut1
C/EBP Jab1-Luc (as a
control) and subjected to luciferase reporter assays, western blot analyses to demonstrate the efficient knockdown of Stat3 and Src protein levels
are shown in the right panel. (b) MDA-MD-468 cells were transfected with increasing doses of siStat3 and siSrc and Jab1 was detected by RT-
PCR, quantification of Jab1 RNA levels is shown in (c). (d) Western blot analysis demonstrates that Jab1 protein levels decreased following
inhibition of Stat3 and Src by siRNA. Jab1, c-Jun activation domain-binding protein-1; Mut, mutation; siRNA, small interfering RNA; RT-PCR, reverse
transcription polymerase chain reaction; STAT, signal transducer and activator of transcription.
Shackleford et al. Breast Cancer Research 2011, 13:R65
http://breast-cancer-research.com/content/13/3/R65
Page 12 of 16the identification of C/EBP-b, GATA-1, and Stat3 as
positive regulators of Jab1 transcription in breast cancer
cells. Promoter deletion studies identified a region
between -472 and -345 that has significant transcrip-
tional activity, as evidenced by the dramatic reduction in
luciferase reporter activity when this region has been
deleted (Figure 2a). Mutation of both the C/EBP and
GATA-1 sites together resulted in decreased luciferase
reporter activity of approximately 75% when combined.
We identified C/EBP, GATA-1, and Stat3 consensus
sequences located in this region and their binding was
confirmed by EMSA and ChIP assays. We established
that C/EBP, GATA-1, and Stat3 are positive regulators
of Jab1 promoter activity. As these transcription factors
are activated during tumorigenesis, and because Jab1 is
overexpressed in a number of tumors, we demonstrate
that these transcription factors indeed increase tran-
scription of Jab1.
In our study, we identified C/EBP as a potential tran-
scriptional activator for Jab1, specifically C/EBPa and
C/EBPb-2. C/EBPb-1 is expressed in normal breast cells
while expression of C/EBPb-2 is known to be expressed
specifically in invasive primary breast tumor samples or
cells lines [39]. Of the three isoforms of C/EBP-b,t h e
transactivating form of LAP2 resulted in a two-fold
increase in Jab1 transcriptional activity while the inhibi-
tor isoform LIP decreased activity. C/EBP-b appears to
play a critical role in the development of both the mam-
mary gland and cancers therein through its involvement
in development, differentiation, and proliferation of
mammary epithelial cells [25,27,31]. As Jab1 is fre-
quently upregulated in breast cancer, it is possible that
Figure 7 Stat3 pathway contributes to Jab1 transcriptional activation and increased protein levels.( a) Increased expression of Stat3 in
the normal mammary epithelial MCF-10A cells increased Jab1 RNA levels as detected by RTPCR, quantification of Jab1 RNA levels is shown in
the bottom panel. (b) Ectopic expression of Flag-Stat3 (0, 1, 2, and 3 μg) in normal mammary epithelial cells (MCF-10A and MCF-10F) resulted in
increased Jab1 protein levels. (c) Treatment with the cytokine IL-6 increased Jab1 mRNA levels - seen by RT-PCR - in both normal MCF-10A and
breast cancer T47D cells that were blocked by the Stat3 inhibitor Stattic. (d) Treatment with IL-6 increased Jab1 protein levels following
activation of Stat3 (P-Stat3 Y705) that was inhibited by the addition of Stattic. (e) Schematic representation of the major molecular mechanism of
Stat3-induced transcriptional activation of Jab1 through two signaling axes - Src/Stat3 and IL-6/Stat3. Jab1, c-Jun activation domain-binding
protein-1; RT-PCR, reverse transcription polymerase chain reaction; STAT, signal transducer and activator of transcription.
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ing the tumorigenic process. Of note, our study detected
higher levels of all three C/EBP-b isoforms in a panel of
breast cancer cell lines compared with normal mam-
mary epithelial cells (Figure 4d), which is contrary to
previous studies that identified mainly higher expression
of LAP2 in breast cancer. Yet, LAP2 was the isoform
that resulted in the greatest increase in transcriptional
activity of Jab1. This increased expression could cer-
tainly be driving increased Jab1 activity in breast cancer
cells.
Further, we identified a co-existing Stat3 binding site
within the C/EBP binding site on the Jab1 promoter.
Ectopic overexpression of Stat3 increased transcriptional
activity as well as mRNA and protein levels of Jab1.
This was further increased with overexpression of the
activated form of Stat3. Constitutive activation of Stat3
occurs commonly in cancer, including breast cancer and
has been demonstrated to contribute to tumorigenic
processes [40]. Stat3 can mediate signaling through
upstream receptor tyrosine kinases such as epidermal
growth factor receptor (EGFR) and platelet-derived
growth factor receptor (PDGR) as well as upstream
non-receptor tyrosine kinases such as Abl and Src-
related kinases. These receptors are constitutively acti-
vated in cancer, typically through genetic alterations
[40]. The oncogenic Src protein kinase itself is overex-
pressed in a large number of tumor types and interacts
with multiple tyrosine kinase receptors, including EGFR
and HER2 [41] to mediate its oncogenic effects of pro-
moting growth and metastasis. We found that Src, an
activator of Stat3, is involved in Jab1 transcription.
Overexpression of both Stat3 and Src in normal mam-
mary epithelial cells resulted in increased Jab1 mRNA
and protein levels. These data provide the first evidence
that Jab1 is a direct downstream target of Stat3 and Src.
Additionally, inhibition of Src by siRNA reduced Jab1
promoter activity in a manner similar to inhibition of
Stat3. We further identified one upstream activator of
Stat3, IL-6, that mediated activation of Jab1 expression.
Since the present study began, Jab1 expression has
been linked to the HER2 signaling pathway. HER2 has
been found to stimulate Jab1 transcriptional activity in
NIH3T3 cells stably expressing the HER2 receptor [21].
This stimulation took place through the AKT/b-catenin/
TCF-4 signaling pathway in breast cancer cells overex-
pressing the HER2 receptor. The TCF binding site is in
t h es a m ea r e aa so u rr e g i o no fi n t e r e s t ,b e t w e e n- 4 7 2
and -344. In our laboratory, we also found overexpres-
sion of Jab1 in NIH3T3 and MCF7 cells that stably
express the HER2 receptor (data not shown). However,
inhibition of this pathway by the anti-HER2 antibody
trastuzumab (Herceptin) or AKT inhibitors in MCF7
and SKBR3 cells did not reduce Jab1 promoter activity.
However, trastuzumab did inhibit Jab1 protein levels in
BT-474 breast cancer cells as well as phosphorylation of
AKT and Stat3 (data not shown). The regulation of Jab1
expression by HER2 through the AKT pathway is of
great interest, and further studies could strengthen our
understanding on the role of Jab1 in the tumorigenic
process.
As overexpression of Jab1 is frequently observed in
breast cancer, further investigation of the pathways that
modulate Jab1 transcription would provide insight into
the role Jab1 plays in the tumorigenic process therein.
Activation of the Stat3 pathway in breast cancer can
occur through many pathways, including those of EGFR,
HER2, IL-6 receptors, IL-11 receptors, and progesterone
receptors [42]. Experimental activation of these path-
ways, followed by evaluation of Jab1 promoter activity
a n dm R N Al e v e l s ,c o u l dp r o v i d ei n s i g h ti n t ot h e
mechanisms by which Jab1 transcription is activated.
Our data provide evidence of activation of Jab1 tran-
scription through IL-6 and Src mediated activation of
S t a t 3a ss h o w ni nF i g u r e7 e .I ti sp o s s i b l et h a to t h e r
activators upstream of Stat3 could be mediating this
downstream effect as well and warrants further
investigation.
Conclusions
In summary, the present study demonstrates that the
Src/Stat3 and C/EBP signaling pathways positively regu-
late the expression of the Jab1 oncogene. Our results
show that Stat3 and LAP2 (C/EBP-b2) are the two
major transcription factors that contribute to Jab1 over-
expression that leads to increased proliferation of breast
cancer cells. Our findings reveal a novel mechanism of
Jab1 regulation and provide functional and mechanistic
links between two major signaling axes - Src/Stat3 and
IL-6/Stat3 - that are involved in controlling Jab1 onco-
genic protein activation. Understanding the mechanisms
by which Jab1 expression is deregulated may help in the
development of drugs that target additional key ele-
ments responsible for this important deregulation.
Additional material
Additional file 1: Figure S1. C/EBP and GATA binding sites homology
from the human and mice promoter regions.Figure S2. IL-6 mediated
activation of Jab1 promoter activity.
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